| PRD_000645 | Name: | (2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-(6-{[(1R)-4-carbamimidamido-1-{[(1R)-4-carbamimidamido-1-carbamoylbutyl]carbamoyl}butyl]amino}-6-oxohexyl)-3,4-dihydroxytetrahydrofuran-2-carboxamide | Formula: | C28 H47 N15 O7 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
| PRD_000672 | Name: | CBZ-ASP-GLU-VAL-azaASP-EP-CO-NH-CH2PH | Formula: | C35 H44 N6 O14 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
| PRD_000673 | Name: | CBZ-ASP-GLU-VAL-azaASP-EP-COO-CH2PH | Formula: | C35 H43 N5 O15 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
| PRD_000674 | Name: | CBZ-ASP-GLU-VAL-azaASP-EP-CO-N(CH2PH)2 | Formula: | C42 H50 N6 O14 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
| PRD_000727 | Name: | PYOVERDIN G173 Fe Complex | Formula: | C49 H66 Fe N13 O21 | Description: | IN IRON-DEFICIENT CONDITIONS, PSEUDOMONAS
AERUGINOSA SECRETES A MAJOR FLUORESCENT
SIDEROPHORE NAMED PYOVERDIN (PVD),
WHICH AFTER CHELATING IRON(III) IS TRANSPORTED
BACK INTO THE CELL VIA ITS OUTER MEMBRANE RECEPTOR
FPVA. FPVA IS A TONB-DEPENDENT TRANSPORT PROTEIN
AND HAS THE ABILITY TO BIND PVD IN ITS APO-
OR IRON-LOADED FORM. | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
| PRD_000770 | Name: | (5S, 8R, 11S)-14-[4-(BENZYLOXY)-4-OXOBUTANOYL]-8-(2-CARBOXYETHYL)-5-(CARBOXYMETHYL)-11-
(1-METHYLETHYL)-3,6,9,12-TETRAOXO-1-PHENYL-2-OXA-4,7,10,13,14-PENTAAZAHEXADECAN-16-OIC ACID | Formula: | C35 H43 N5 O14 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
| PRD_000781 | Name: | Thr-Asp-F-amidine | Formula: | C17 H29 F N6 O7 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
| PRD_000785 | Name: | Largazole | Formula: | C21 H29 N4 O4 S3 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
| PRD_000814 | Name: | N-{[(3R,4R,7S,10R,11R)-3-ethyl-11,15-dihydroxy-3-methyl-10-(methylamino)-6,9-dioxo-7-(propan-2-yl)-2-oxa-5,8-diazabicyclo[10.3.1]hexadeca-1(16),12,14-trien-4-yl]carbonyl}glycine | Formula: | C23 H34 N4 O8 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
| PRD_000823 | Name: | N-propanoyl-D-alanyl-(4R)-4-[(7-bromoisoquinolin-1-yl)oxy]-N-{(1R,2R)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}-L-prolinamide | Formula: | C29 H34 Br N5 O7 S | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
| PRD_000842 | Name: | PTA-SFTI INHIBITOR | Formula: | C66 H106 N20 O18 S2 | Description: | Bowman-Birk Inhibitor | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
| PRD_000845 | Name: | N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-7-methoxy-2-{2-[(2-methylpropanoyl)amino]-1,3-thiazol-4-yl}quinolin-4-yl)oxy]-N-[(1R,2S)-1-carboxy-2-ethenylcyclopropyl]-L-prolinamide | Formula: | C40 H49 Br N6 O9 S | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
| PRD_000846 | Name: | TRYPSIN INHIBITOR 1 | Formula: | C66 H106 N20 O18 S2 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
| PRD_000849 | Name: | N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-{2-[(2-methylpropanoyl)amino]-1,3-thiazol-4-yl}quinolin-4-yl)oxy]-L-prolinamide | Formula: | C40 H50 N6 O9 S | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
| PRD_000857 | Name: | SAH-p53-8 stapled-peptide | Formula: | C96 H151 N26 O25 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
| PRD_000894 | Name: | MM-102 | Formula: | C35 H50 F2 N7 O4 | Definition date: | 2013-07-31 | Last modified: | 2023-11-03 |
|
| PRD_000895 | Name: | MM-101 | Formula: | C35 H52 N7 O4 | Definition date: | 2013-07-31 | Last modified: | 2023-11-03 |
|
| PRD_000896 | Name: | MM-402 | Formula: | C31 H51 N8 O5 | Definition date: | 2014-02-19 | Last modified: | 2023-11-03 |
|
| PRD_000897 | Name: | MM-401 | Formula: | C29 H47 N8 O5 | Definition date: | 2014-02-19 | Last modified: | 2023-11-03 |
|
| PRD_000901 | Name: | thiomuracin A derivative | Formula: | C53 H54 N13 O9 S6 | Definition date: | 2012-12-26 | Last modified: | 2023-11-03 |
|
| PRD_000913 | Name: | M4Z inhibitor | Formula: | C24 H39 N7 O6 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
| PRD_000930 | Name: | N-hexanoyl-L-valyl-N~1~-[(2R,3S,4S)-1,3-dihydroxy-2,6-dimethylheptan-4-yl]-N~5~,N~5~-dimethyl-L-glutamamide | Formula: | C27 H52 N4 O6 | Description: | epoxyketone carmaphycin analogue 3, bound form | Definition date: | 2014-01-29 | Last modified: | 2023-11-03 |
|
| PRD_000935 | Name: | N-[(benzyloxy)carbonyl]-6-diazonio-5-oxo-L-norleucyl-L-valyl-L-prolyl-L-leucine | Formula: | C30 H43 N6 O8 | Definition date: | 2013-06-26 | Last modified: | 2023-11-03 |
|
| PRD_000956 | Name: | N-[(2S)-1-({(2S)-1-{[(2R,3S,4S)-1,3-dihydroxy-2,6-dimethylheptan-4-yl]amino}-4-[(R)-methylsulfinyl]-1-oxobutan-2-yl}amino)-3-methyl-1-oxobutan-2-yl]hexanamide | Formula: | C25 H49 N3 O6 S | Description: | Carmaphycin A, bound form | Definition date: | 2014-01-29 | Last modified: | 2023-11-03 |
|
| PRD_000988 | Name: | N-benzoyl-L-norleucyl-6-ammonio-L-norleucyl-N~5~-[amino(iminio)methyl]-N-[(2S)-5-carbamimidamido-1-hydroxypentan-2-yl]-L-ornithinamide | Formula: | C31 H57 N11 O5 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|